Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.
Zhaohui JinFrank A SinicropePublished in: Cancers (2021)
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.
Keyphrases
- metastatic colorectal cancer
- newly diagnosed
- clinical practice
- end stage renal disease
- healthcare
- case report
- ejection fraction
- squamous cell carcinoma
- peritoneal dialysis
- small cell lung cancer
- palliative care
- prognostic factors
- papillary thyroid
- multidrug resistant
- late onset
- quality improvement
- gene expression
- dna repair
- genome wide
- machine learning
- dna methylation
- replacement therapy
- risk assessment
- smoking cessation
- dna damage
- patient reported
- chronic pain
- human health
- drug induced
- lymph node metastasis